Disitamab vedotin targets HER2 on the cell surface, is internalized, and releases MMAE, which binds beta-tubulin (vinca domain) to block microtubule polymerization and induce G2/M arrest and apoptosis. Killing depends on HER2-directed delivery, not on beta-tubulin expression alone.